(84 days)
Not Found
No
The description focuses on the mechanical aspects of a pen-injector for insulin and does not mention any computational or data-driven features indicative of AI/ML.
No.
The device is a self-injection device that delivers insulin, but it does not exert its therapeutic effect on the body itself. The therapeutic effect comes from the insulin it delivers.
No
The device is described as an injection device for insulin and its function is to deliver medication, not to diagnose a condition.
No
The device description clearly states it is a "reusable pen-injector" and describes physical components like a "single lumen hypodermic needle" and compatibility with "3.0-mL cartridges." This indicates a hardware device, not software only.
Based on the provided information, the TactiPen is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is for the subcutaneous injection of insulin. This is a therapeutic action, delivering a substance into the body.
- Device Description: The description details a mechanical device for delivering medication. It does not mention any components or processes related to examining specimens from the human body to provide diagnostic information.
- Lack of Diagnostic Function: There is no mention of the device being used to diagnose, monitor, or screen for any condition. Its sole purpose is to administer insulin.
IVD devices are used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health status, diagnose diseases, or monitor treatment. The TactiPen does not perform any such function.
N/A
Intended Use / Indications for Use
The TactiPen is a self injection device intended to deliver a subcutaneous injection of U-100 insulin from a 3-mL cartridge.
Product codes (comma separated list FDA assigned to the subject device)
FMF
Device Description
The TactiPen is a reusable pen-injector designed to provide a method of accurately subcutaneously injecting the desired dose of U-100 insulin from a single lumen hypodermic needle. The device can be used by health professionals or for self-injection by the patient. The pen-injector uses 3.0-mL cartridges of U-100 insulin and a single use, detachable and disposable needle (supplied separately). The pen injector allows the user to dial the desired dose. The device is compatible with commercially available pen needles (supplied separately) that comply with: ISO 11608-2:2000 Pen-injectors for medical use - Part 2: Needles - Requirements and test method and 3-mL ISO type A cartridges (supplied separately), which meet ISO 11608-3: 2000 Pen-injectors for medical use - Part 3: Finished cartridges - Requirements and test methods.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
health professionals or for self-injection by the patient.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The TactiPen has been demonstrated to perform as intended. The TactiPen conforms to the requirements when tested using the methods specified in the ISO Standard, ISO 11608-1:2000, "Pen-injectors for Medical Use - Part 1 Requirements and Test Methods."
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5860 Piston syringe.
(a)
Identification. A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.(b)
Classification. Class II (performance standards).
0
510(k) Premarket Notification Haselmcier GmbH TactiPen
K083457
510(k) Summary
Page 1 of 2
510(k) SUMMARY
[as required by section 807.92(c)]
FEB 1 3 7009
General Information
Submitted by:
Contact Person:
Haselmeier GmbH Dufourstr. 32 CH-8008 Zurich Switzerland
Robert J. Kilgore
Haselmeier USA 517 Benfield Road Suite 301 Severna Park, MD 21146-2596
Phone: 410 647-7300 Fax: --410 647-7383 Email: r.kilgore@haselmeier.com
Date Prepared:
October 2, 2008
Device Name
Trade Name: Common Name: Classification Number: Product Code:
TactiPen Piston syringe 880.5860 FMF
Predicate Devices
Haselmeier Pen | K070100 | Haselmeier GmbH |
---|---|---|
Disetronic Pen | K982966 | Disetronic Medical System |
HumaPen and HumaPen Ergo | K982842 | Eli Lilly and Company |
Device Description
The TactiPen is a reusable pen-injector designed to provide a method of accurately subcutaneously injecting the desired dose of U-100 insulin from a single lumen hypodermic needle. The device can be used by health professionals or for selfinjection by the patient.
1
510(k) Summary
The pen-injector uses 3.0-mL cartridges of U-100 insulin and a single use, detachable and disposable needle (supplied separately). The pen injector allows the user to dial the desired dose.
The device is compatible with commercially available pen needles (supplied separately) that comply with: ISO 11608-2:2000 Pen-injectors for medical use - Part 2: Needles - Requirements and test method and 3-mL ISO type A cartridges (supplied separately), which meet ISO 11608-3: 2000 Pen-injectors for medical use - Part 3: Finished cartridges - Requirements and test methods.
Intended Use
The TactiPen is a self injection device intended to deliver a subcutaneous injection of U-100 insulin from a 3-mL cartridge.
Technological Comparison
The TactiPen has similar indications for use and overall function and performs in a similar manner with respect to the Haselmeier Pen, Disetronic Pen, HumaPen, and HumaPen Ergo.
The technological characteristics of the TactiPen and its drug cartridge are the same as product currently legally marketed in the USA.
Performance Data
The TactiPen has been demonstrated to perform as intended.
The TactiPen conforms to the requirements when tested using the methods specified in the ISO Standard, ISO 11608-1:2000, "Pen-injectors for Medical Use - Part 1 Requirements and Test Methods."
Conclusion
Haselmeier concludes based on the information presented that the TactiPen is substantially equivalent to products currently, legally marketed in the USA.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal on the left and a stylized symbol on the right. The seal contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" arranged around the perimeter of the circle.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FEB 1 3 2009
Haselmeier GmbH C/o Mr. Stephen J. Goldner, JD, RAC President Regulatory Affairs Associates 30833 Northwestern Highway, Suite 121 Farmington Hill, Michigan 48334-2581
Re: K083457
Trade/Device Name: TactiPen Regulation Number: 21 CFR 880.5860 Regulation Name: Piston Syringe Regulatory Class: II Product Code: FMF Dated: November 20, 2008 Received: November 21, 2008
Dear Mr. Goldner:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 .- Mr. Goldner
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Anthony, D., Addison for
Ginette Y. Michaud, M.D. Acting Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Premarket Notification Haselmeier GmbH TactiPen
Indications for Use
Page 1 of 1
INDICATIONS FOR USE
510(k) Number (if known):
Device Name:
Sponsor Name:
Indications for Use:
TactiPen
・・
Haselmeier GmbH
The TactiPen is a self injection device intended for the subcutaneous injection of U-100 insulin from a 3-mL cartridge.
Prescription Use X (21 CFR 801 Subpart D) Or
Over-The-Counter Use (21 CFR 807 Subpart C)
Do Not Write Below This Line – Continue on Another Page if Needed
Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) (Division Sign-Stil)
Division of Anesthesiology, General Hospital Division Control, Dental Devices
510(k) Number: K683457